Nicolas Bihoreau
25Patents
6h-index
22Co-inventors
69Inventor score
Filing activity: Feb 7, 1995 → Jun 7, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7713524B2 | Use of ADCC-optimized antibodies for treating low-responder patients | Emerging Cross-Sectional Technologies | 26 | Expired |
| US8685725B2 | Monoclonal antibodies with enhanced ADCC function | Chemistry; Metallurgy | 19 | Active |
| US7931895B2 | Monoclonal antibodies with enhanced ADCC function | Chemistry; Metallurgy | 19 | Expired |
| US7579170B2 | Method for preparing monoclonal antibodies capable of activating effector cells expressing FCγRIII | Chemistry; Metallurgy | 17 | Expired |
| US5707832A | Process for the preparation of human factor VIII and analogs of factor VIII | Human Necessities | 8 | Expired |
| US8501171B2 | Use of ADCC-optimized antibodies for treating weak patients | Emerging Cross-Sectional Technologies | 6 | Active |
| US8409572B2 | Monoclonal antibodies with enhanced ADCC function | Chemistry; Metallurgy | 3 | Active |
| US7541029B2 | Anti-rhesus D monoclonal antibodies | Chemistry; Metallurgy | 3 | Active |
| US10364425B2 | Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units | Human Necessities | 2 | Active |
| US10344272B2 | Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units | Human Necessities | 2 | Active |
| US8153124B2 | Method for treating cancer using monoclonal antibodies | Chemistry; Metallurgy | 2 | Active |
| US9212365B2 | Method for purifying active GLA-domain coagulation proteins | Chemistry; Metallurgy | 1 | Active |
| US9708409B2 | Monoclonal antibodies with enhanced ADCC function | Chemistry; Metallurgy | 1 | Active |
| US9359610B2 | Method for purifying GLA-domain coagulation proteins | Chemistry; Metallurgy | 1 | Active |
| US9718889B2 | Monoclonal antibodies with enhanced ADCC function | Chemistry; Metallurgy | 1 | Active |
| US9718890B2 | Monoclonal antibodies with enhanced ADCC function | Chemistry; Metallurgy | 1 | Active |
| US7790399B2 | Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors | Chemistry; Metallurgy | 1 | Expired |
| US9879089B2 | Use of ADCC-optimized antibodies for treating low-responder patients | Emerging Cross-Sectional Technologies | 0 | Active |
| US8178093B2 | Method for treating infectious disease using monoclonal antibodies | Chemistry; Metallurgy | 0 | Active |
| US8357370B2 | Anti-D monoclonal antibodies | Chemistry; Metallurgy | 0 | Active |
| US10081683B2 | Monoclonal antibodies with enhanced ADCC function | Chemistry; Metallurgy | 0 | Active |
| US8124078B2 | Method for treating idiopathic thrombocytopenic purpura using monoclonal antibodies | Chemistry; Metallurgy | 0 | Active |
| US9109020B2 | Use of ADCC-optimized antibodies for treating weak patients | Emerging Cross-Sectional Technologies | 0 | Active |
| US9850477B2 | Method for purifying active GLA-domain coagulation proteins | Chemistry; Metallurgy | 0 | Active |
| US7595165B2 | Method of measuring activation of effector cells | Physics | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.